Friday, March 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

What will the Covid-19 pandemic look like in 2022?

The Economist’s modelling suggests that covid-19 has killed between 10.8m and 20m people, with a best estimate of 17.3m thus far. In most rich countries vaccines are breaking the link between infections and deaths, and restrictions have eased. In other places, such as eastern Europe, deaths are rising amid a new wave of infections. What should the world expect next year?

The virus will not be eradicated. Only one disease, smallpox, has ever been eliminated. Instead, global immunity will increase as more people are vaccinated or contract covid-19. Some 3.8bn have had at least one jab and 2.8bn are fully vaccinated. Together with those who have caught the disease, around half the world’s population has some level of immunity. Eventually, covid-19 will become endemic: transmission will remain at a steady rate, following seasonal patterns, with fewer spikes in infection. The harm caused may end up somewhere between that of influenza, which kills an estimated 300,000 to 650,000 people annually, and of other coronaviruses, such as the common cold. But endemicity is still a long way off for most countries. Deaths in eastern Europe show the risks in places where vaccination rates remain low. In a best-case scenario, covid-19 could begin to follow a seasonal pattern by 2025. But it will take decades for people to become as immune to it as they are to the common cold.

Source: The Economist

https://www.economist.com/the-economist-explains/2021/11/19/what-will-the-covid-19-pandemic-look-like-in-2022

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!